Patient-specifc classifcations of human malignant disease

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 3, 2009, Pages 252-259

  Parkinson, David R ^a   Cesano, Alessandra ^a  

^a Nodality Inc   (United States)

Author keywords

Biomarker; Cancer; Disease classifcation; Flow cytometry; Gene expression; Genomic sequencing

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; BREAST CANCER; CANCER CLASSIFICATION; CANCER PATIENT; CHROMOSOME ANALYSIS; DNA MICROARRAY; GENETIC ANALYSIS; GENETIC MARKER; HUMAN; IMMUNOPHENOTYPING; MUTATIONAL ANALYSIS; NEOPLASM; NONHODGKIN LYMPHOMA; PATIENT CODING; PROGNOSIS; REVIEW; CLASSIFICATION;

HUMANS; NEOPLASMS;

EID: 67650224645     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Hanahan D, Weinberg RA: The Hallmarks of Cancer. Cell (2000) 100(1):57-70.
2. How news drugs move through the development and approval process: Tufts University, Boston, MA, USA (2009). csdd.tufts.edu/ NewsEvents/RecentNews.asp?newsid=4
3. Sobin LH: TNM evolution and relation to other prognostic factors. Semin Surg Oncol (2003) 21(1):3-7.
4. Lukes R, Collins R: Immunologic characterization of human malignant lymphomas. Cancer (1974) 34(4 Suppl):1488-1503.
5. Vardiman JW, Brunning RD, Arber DA, Le Beau MM, Porwit A, Tfferi A, Bloomfeld CD and Thiele J: Introduction and overview of the classifcation of the myeloid neoplasms. In: WHO classifcation of tumors of haematopoietic and lymphoid tissues. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Eds), WHO, Geneva, Switzerland (2008):18-30.
6. Ludwig JA, Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer (2005) 5(11):845-856.
7. Giaccone G: Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol (2005) 23(14):3235-3242.
8. Rye P, Rittenhouse H, Stigbrand T: Up close and personal: Molecular diagnostics in oncology. Tumor Biol (2004) 25(4):217-220.
9. Volgelstein B, Kinzler KW: Cancer genes and the pathway they control. Nat Med (2004) 10(8):789-799.
10. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S et al: The consensus coding sequences of human breast and colorectal cancers. Science (2006) 314(5797):268-274.
11. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N et al: The genomic landscapes of human breast and colorectal cancers. Science (2007) 318(5853):1108-1113.
12. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 321(5897):1801-1806.
13. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A et al: An intergrated genomic analysis of human glioblastoma multiforme. Science (2008) 321(5897):1807-1812.
14. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfeld CD et al: Molecular classifcation of cancer: Class discovery and class prediction by gene expression monitoring. Science (1999) 286(5439):531-537.
15. Irish JM, Kotecha N, Nolan GP: Mapping normal and cancer cell signaling networks: Towards single-cell proteomics. Nat Rev Cancer (2006) 6(2):146-155.
16. Quackenbush J: Microarray analysis and tumor classifcation. N Engl J Med (2006) 354(23):2463-2470.
17. Döhner H: Implication of the molecular characterization of acute myeloid leukemia. Hematology Am Soc Hematol Educ Prog (2007):412-419.
18. Marcucci G, Mrózek K, Bloomfeld C: Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol (2005) 12(1):68-75.
19. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 358(18):1909-1918.
20. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu C-G, Ruppert AS et al: Prognostic signifcance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A Cancer and Leukemia Group B Study. J Clin Oncol (2008) 26(31):5078-5087.
21. Whitman SP, Ruppert AS, Radmacher MD, Mrózek K, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell BL, Kolitz JE et al: FLT3 D845/I836 mutations are associated with poor disease-free survival and a distinct gene expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood (2008) 111(3):1552- 1559.
22. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, Haferlach T, Hiddemann W, Falini B: Nucleophosmin gene mutations are predictors of favorable prognosis in acute myeloid leukemia with normal karyotype. Blood (2005) 106(12):3733-3739.
23. Fröhing S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K: CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Invest (2004) 22(4):624-633.
24. Vey N, Mozziconacci MJ, Groulet-Martinec A, Debono S, Finetti P, Carbuccia N, Beillard E, Devilard E, Arnoulet C, Coso D, Sainty D et al: Identifcation of new classes among acute myelogenous leukemias with normal karyotype using gene expression profling. Oncogene (2004) 23(58):9381-9391.
25. Bullinger L, Döhner K, Bair E, Fröhling S, Schlenk R, Tibshirani R, Döhner H, Pollack J: Use of gene-expression profling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med (2004) 350(16):1605-1615.
26. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB, Su X et al: Genome wide analysis of genomic alterations in acute lymphoblastic leukemias. Nature (2007) 446(7137):758-764.
27. The Non-Hodgkin's Lymphoma Classifcation Project (1997): A clinical evaluation of the International Lymphoma Study Group classifcation of non-Hodgkin's Lymphoma. Blood (1997) 89(11):3903-3918.
28. Coiffer B: Diffuse large cell lymphoma. Curr Opin Oncol (2001) 13(5):325-334.
29. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI et al: Distinct types of diffuse large B-cell lymphoma identifed by gene expression profling. Nature (2000) 403(6769):503-511.
30. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM et al: The use of molecular profling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med (2002) 346(25):1937- 1947.
31. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM: A gene expression based method to diagnose clinically distinct subgroups of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA (2003) 100(17):9991-9996.
32. Staudt LM, Dave S: The biology of human lymphoid malignancies revealed by gene expression profles. Adv Immunol (2005) 87:163-208.
33. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J et al: Molecular subtype of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA (2008) 105(36): 13520-13525.
34. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP et al: Prediction of survival in follicular lymphoma based on molecular features of tumor-infltrating immune cells. N Engl J Med (2004) 351(21):2159-2169.
35. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE: Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst (2004) 96 218-228.
36. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol (2005) 16(10):1569-1583.
37. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA (2001) 98(19):10869- 10874.
38. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J et al: Repeated observation of breast tumors subtypes in independent gene expression data sets. Proc Natl Acad Sci USA (2003) 100(14):8418-8423.
39. Yu K, Lee CH, Tan PH, Tan P: Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res (2004) 10(16):5508-5517.
40. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 7:96-101.
41. Peppercorn J, Perou CM, Carey LA: Molecular subtypes in breast cancer evaluation and management: Divide and conquer. Cancer Invest (2008) 26(1):1-10.
42. Foekens JA, Wang Y, Martens JW, Berns EM, Klijn JG: The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine. Drug Discov Today (2008) 13(11-12):481- 487.
43. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner EL, Walker MG, Watson D, Park T, Hiller W et al: Multygene assay to predict recurrence to tamoxifen-treated, node-negative breast cancer. (2004) 351(27):2817-2826.
44. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A et al: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Nat Cancer Inst (2006) 98(17):1183-1192.
45. Wang Y, Kiljn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T et al: Gene-expression profles to predict distant metastasis of lymph-node negative primary breast cancer. Lancet (2005) 365(9460):671-679.
46. In vitro diagnostic multivariate index assays - Draft guidance for industry, clinical laboratories, and FDA staff. FDA, Silver Spring, MD, USA (2007). www.fda.gov/cdrh/oivd/guidance/1610.html
47. Jing Y. The PML-RARα fusion protein and targeted therapy for acute promyelocytic leukemia. Leuk Lymphoma (2004) 45: 639-648.
48. Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA, Downing JR: Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 322(5906):1377-1380.
49. Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, Diaz-Flores E, Coram M, Shannon KM, Nolan GP, Loh ML: Single-cell profling identifes aberrant STAT5 activation in myeloid malignancies with specifc clinical and biologic correlates. Cancer Cell (2008) 14(4):335-343.
50. Irish JM, Hovland R, Krutzik PO, Perez OD, Gjertsen BT, Nolan GP. Single cell profling of potentiated phospho-protein networks in cancer cells. Cell (2004) 118(2):217-228.
51. Table of valid genomic biomarkers in the context of approved drug labels. FDA, Silver Spring, MD, USA (2009). www.fda.gov/cder/ genomics/genomic-biomarkers-table.htm
52. Genentech fles citizen petition urging FDA to regulate all lab-developed tests. GenomeWeb, New York, NY, USA (2008). www.genomeweb.com/genentech-fles-citizen-petition-urging-fda-regulate-all- lab-developed-tests
53. Oncologic Drugs Advisory Committee: FDA, Silver Spring, MD, USA (2008). www.fda.gov/ohrms/dockets/ac/cder08.html#OncologicDrugs
54. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposals for the classifcation of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol (1976) 33(4):451-458.
55. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classifcation of the myeloid neoplasms. Blood (2002) 100(7):2292-2302.